MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032
Zurich, August 03, 2016. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries.
This expands the list of countries in which MetrioPharm has broad protection for MP1032 from Europe, the USA, Australia, New Zealand, Israel, and China to further include Russia and South Africa.
The Russian Patent No. RU2585677C2 was effectively granted on June 16, 2016 by publication of the patent specification. The South African patent No. ZA2012/06264 was issued just recently, on July 27, 2016.
"The granting of patents in Russia and South Africa further improves our already strong IP position," comments Dr. Wolfgang Brysch, CEO of MetrioPharm AG. Currently, comprehensive patent protection exists for MP1032 in all major markets. In a few countries, the divisional applications are still pending.
"Based on the successful granting history of our MP1032 patent family we are confident that all remaining pending applications will be granted in due course," explains Dr. Brysch.
MetrioPharm's proprietary drug candidate MP1032 is a novel synthetic smallmolecule drug with strong anti-inflammatory properties and an excellent toxicity profile in pre-clinical studies. MP1032 belongs to a new class of macrophagemodulatory drugs that act on the innate immune system. MP1032 targets the molecular activation mechanisms of inflammatory macrophages. These cells drive the inflammation, pain and tissue damage in a wide range of inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, musculo-skeletal injuries and multiple sclerosis.
MetrioPharm is a clinical-stage drug development company with legal base in Zurich and an R&D location in Berlin. The company develops a breakthrough class of new anti-inflammatory and immunemodulating drugs against chronic inflammatory and autoimmune diseases.